Depression and Anxiety Levels in Armenian Crohn's Disease Patients

Authors: Astghik Z. Pepoyan, Elya S. Pepoyan

Abstract:

The Zung self-depression scale and Beck Anxiety Inventory were used to study the depression and anxiety levels of Armenian Crohn's disease patients, as well as to reveal the relation between emotional status and placebo effect of these patients. Despite of registered high levels of depression and anxiety, the high placebo rate during investigations was described. The importance of use of psychotherapies for optimal outcomes during treatments of Crohn's disease is obvious.

Keywords: Crohn's disease, emotional disorders, placebo, psychotherapy.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1055238

References:

[1] T. Alander, K. Svardsudd, S. Johansson, and L. Agreus, "Psychological illness is commonly associated with functional gastrointestinal disorders and is important to consider during patient consultation: a populationbased study", BMC Med, vol. 13, 2005, pp. 3-8.
[2] Bardel, "Factors associated with adherence to drug therapy: a population-based study", Eur J Clin Pharmacol, vol. 63, no. 3, 2007, pp. 307-314.
[3] Beck and R. Steer, Beck Anxiety Inventory Manual. San Antonio, TX: The Psychological Corporation Harcourt Brace and Company, 1993.
[4] Crohn, "Regional Ileitis", Ed. New York: Grune and Stratton, 1949, pp. 15-64.
[5] Drossman, F. Creed, K. Olden, J. Svedlund, B. Toner, and W. Whitehead, "Psychosocial aspects of functional gastrointestinal disorders", Gut, vol. 45, 1999, pp. 1125-1130.
[6] Gerbert, "Psychological aspects of Crohn's disease", Journal of Behavioral Medicine, vol. 3, 1980, pp. 41-58.
[7] J. Kirsner, "Historical origins of current IBD concepts", World J Gastroenterol., vol. 7, no.2, 2001, pp. 175-184.
[8] L. Kurina, M. Goldacre, D. Yeates, and L. Gill, "Depression and anxiety in people with inflammatory bowel disease", J Epidemiol Community Health, vol. 55, 2001, pp. 716-720.
[9] J. Mawdsley, and D. Rampton, "Psychological stress in IBD: new insights into pathogenic and therapeutic implications" Gut., vol. 55, no. 7, 2006, pp. 1053-1054.
[10] Sands, R. Kozarek, J. Spainhour, C. Barish, S. Becker, L. Goldberg, S. Katz, R. Goldblum, R. Harrigan, D. Hilton, and Hanauer, "Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab", Inflamm Bowel Dis., vol. 13, no. 1, 2007, pp. 2-11.
[11] W. Zung, "A Self-rating Depression Scale Scale", Archives of General Psychiatry, vol. 12, 1965, pp. 63-70.